On October 1, 2025, Biomap, a biotechnology start-up co-established by Baidu founder Robin Li Yanhong, announced it has surpassed Alphabet subsidiary AlphaFold in commercializing artificial intelligence foundation models for drug discovery. Biomap is also backed by the Hong Kong government.
Wei Liu, co-founder and CEO of Biomap, stated that multinational pharmaceutical companies were observing a 'reverse' in the technological gap between Biomap and AlphaFold. This indicates a significant advancement in the application of AI for complex scientific problems.
This development showcases Baidu's strategic investments in diverse AI applications, extending its influence into high-impact sectors like biotechnology. The potential for AI-driven drug discovery represents a substantial long-term opportunity.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.